Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Losartan

Drug Profile

Losartan

Alternative Names: Cozaar; Cozaarex; DUP 753; Lortaan; Losaprex; Losartan potassium; MK 954; Neo Lotan; Nu-Lotan; Oscaar

Latest Information Update: 30 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Banyu; M S Jacovides & Co; Merck & Co; Merck Sharp & Dohme; Neopharmed Gentili; S Riesel; sigma-tau SpA
  • Class Antihypertensives; Biphenyl compounds; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies; Heart failure; Hypertension

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Jun 2012 Merck & Co. completes enrolment in its Phase-III trial for Hypertension (in children and infants aged 6 months to 6 years) in USA, European Union, Latin America, India, Norway, Philippines and Russia (NCT00756938)
  • 26 Jan 2012 Generic equivalent available in Canada for Hypertension & Diabetic nephropathies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top